Several decisions made in France during the year 2026 are significantly changing the way prevention, vaccination, and antibiotic prescriptions are regulated. These developments, driven by the Haute Autorité de santé (HAS), the Court of Auditors, or the Senate, affect various aspects of daily medical practice, from dental offices to maternity wards.
Antibiotics in dental care: what the HAS changed in September 2026
Competitors largely cover chronic pathologies or vaccination campaigns. One topic that goes more unnoticed is the prescription of antibiotics during dental care. On September 14, 2026, the HAS published recommendations aimed at reducing unnecessary prescriptions in this area.
The central point concerns antibiotic prophylaxis, which means taking antibiotics before a dental procedure to prevent an infection. Until now, this practice remained common, sometimes more out of reflex than clinical necessity. The HAS now recommends not to use it systematically. When it remains necessary, it should complement a local treatment of the cause of the infection, rather than replace it.
This orientation is part of the fight against antibiotic resistance, a public health issue that goes beyond just the dental field. To follow the recent developments affecting health on Veridictus, this type of sectoral recommendation illustrates how technical decisions ultimately modify daily practices.
Prevention and funding: the proposals of the Senate report from June 2026
A Senate report published on June 24, 2026 proposes to make prevention a structuring axis of health funding in France. Among the proposed measures, three stand out.
- The creation of a new national public health strategy, aimed at setting multiannual priorities for prevention rather than limiting itself to one-off plans.
- The integration of a digital prevention booklet into My health space, the tool already deployed by Health Insurance, to centralize screening actions and vaccinations for each insured person.
- Increased involvement of complementary health insurance in the financing and organization of prevention, beyond their current role of reimbursing curative care.
These proposals do not yet have legal value. They outline a scenario where prevention would no longer be an addition but a criterion for resource allocation. Field feedback varies on the feasibility of such a shift, particularly because complementary health insurance does not all have the same investment capabilities.
Vaccination in France: the Court of Auditors calls for more real-world data
On September 7, 2026, the Court of Auditors made public a report on French vaccination policy. Its findings focus less on the principle of vaccination than on the method of evaluating new vaccines.
The Court recommends better comparison of three parameters before integrating a vaccine into the schedule or recommending it on a large scale:
- The real-world effectiveness of the vaccine, measured after its deployment and not just during clinical trials.
- Its safety profile in large and diverse populations.
- Its cost relative to the observed benefits, which health economists refer to as efficiency.
The Court also advocates for a reorganization of vaccine evaluation by the end of 2027. The stated goal is to have real-world data more quickly after a vaccine is marketed, to adjust recommendations if necessary.
The available data do not allow for conclusions about the exact gap between the effectiveness measured in clinical trials and that observed in real-world conditions for each vaccine. This lack is precisely what the report highlights.
What this changes for patients
In the short term, nothing concrete in the prescription or vaccination booklet. However, if the recommendations of the Court of Auditors are followed, future decisions to extend or withdraw vaccines from the vaccination schedule could rely on more transparent and better-documented criteria.
Screening for cytomegalovirus in pregnant women: a strengthened protocol
Cytomegalovirus (CMV) is a viral infection that is often asymptomatic in adults but can cause severe neurological sequelae in the fetus if there is a primary infection during pregnancy. Since June 2025, the HAS has recommended systematic screening for pregnant women whose serological status is unknown.
This recommendation marks a paradigm shift. Previously, CMV screening was not systematically offered, partly because there was no validated antiviral treatment for seronegative pregnant women. The arrival of new therapeutic options has changed the benefit-risk analysis.
Screening is based on serology performed early in pregnancy. If the woman is not immune, close monitoring allows for the detection of any seroconversion and earlier intervention. Systematic CMV screening aims to reduce congenital infections that previously went unnoticed until birth.
Everyday health: underlying signals to watch
These four topics share a common trait: they do not make headlines, but they tangibly change medical practice or patient rights. The reduction of antibiotics in dental care, the digital prevention booklet, the enhanced evaluation of vaccines, and CMV screening all stem from recent institutional decisions.
Their implementation depends on different timelines. Some recommendations, like those from the HAS on dental antibiotics, are directed specifically at practitioners. Others, like the Senate proposals on prevention, require legislative voting.
Keeping up with health news means distinguishing what is adopted from what remains in the proposal stage. This distinction prevents taking for granted measures still under discussion or ignoring changes already in effect in medical offices.
